Streetbeat News

Regulatory

GAL

Galimedix Therapeutics has initiated a Phase 2 study for GAL-101 eye drops targeting dry age-related macular degeneration (AMD). This study aims to evaluate the efficacy and safety of the treatment in patients with geographic atrophy, a severe form of dry AMD.

Portfolio Pulse from

December 23, 2024 | 4:45 pm

GOOGL

Alphabet (GOOGL) is challenging the U.S. government's demand to sell its Chrome web browser, labeling the action as 'extreme' and arguing that anticompetitive conduct must align with specific violations.

Portfolio Pulse from

December 23, 2024 | 4:30 pm

CATX

Perspective Therapeutics is making strides in oncology with its radiopharmaceuticals, showing early success in neuroendocrine tumors. Their theranostics approach, which combines diagnostics with targeted therapeutics, aims to minimize damage to healthy tissue. Key candidates VMT01 and VMT-α-NET are in Phase 1/2 trials, with VMT01 receiving Fast Track Designation.

Portfolio Pulse from

December 23, 2024 | 4:30 pm

GOOG

Google has proposed a revision of its search deals to address a U.S. antitrust ruling. This could impact its status as the default search engine on Apple devices.

Portfolio Pulse from

December 23, 2024 | 4:30 pm

LLY

Eli Lilly's obesity drug Mounjaro has been approved by the UK's NICE for use in the NHS, making it available to some patients starting March.

Portfolio Pulse from

December 23, 2024 | 4:00 pm

TLN

Talen Energy's request for a rehearing on amendments to the Susquehanna ISA was deferred by FERC. The amendments aimed to increase load capacity at Talen's Susquehanna facility.

Portfolio Pulse from

December 23, 2024 | 4:00 pm

LLY

Eli Lilly and Co (NYSE:LLY) received FDA approval for its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity, marking the first such treatment in the U.S.

Portfolio Pulse from

December 23, 2024 | 4:00 pm

ACLX

The biotech sector experienced a downturn in the second half of the year due to disappointing sales, profit reports, guidance cuts, pipeline setbacks, and the appointment of a vaccine skeptic as head of Health and Human Services.

Portfolio Pulse from

December 23, 2024 | 4:00 pm

PALAF

Levi & Korsinsky has initiated an investigation into Paladin Energy Ltd (OTCQX:PALAF) for potential violations of federal securities laws. This follows Paladin's recent announcement regarding the Langer Heinrich Mine update and FY2025 guidance revision.

Portfolio Pulse from

December 23, 2024 | 3:45 pm

BIOA

Levi & Korsinsky is investigating BioAge Labs, Inc. (NASDAQ:BIOA) for potential securities fraud after the company halted its STRIDES Phase 2 trial due to safety concerns.

Portfolio Pulse from

December 23, 2024 | 3:45 pm